‘Doing more with less’: In-house counsel on budgets and strategy

Chuck Scholtz, head of IP at Verdiva Bio, shares the pressures of global filing strategies on tight budgets, why there’s no ‘right way’ to manage IP, and how to get the best results from external counsel relationships.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Biotech

Regeneron and Amgen call a truce on two Eylea biosimilar patents

28 October 2026 Both companies have agreed to dismiss claims and counterclaims involving Amgen’s 2 mg aflibercept biosimilar, while their wider feud continues.

Biotech

10x and Parse set to end sequencing feud after appeals court defeat

23 October 2026 Following the Federal Circuit’s decision to uphold the invalidation of three patents, the parties are set to drop their remaining claims, despite 10x’s separate multi-million dollar jury win.

Biotech

Guardant loses second patent challenge to TwinStrand amid $245m damages fallout

16 October 2026 All 30 claims of a key DNA sequencing patent have been upheld for a second time, marking another setback in a long-running dispute that has already left Guardant facing a $245 million bill.

More features

Fenwick hires NY partner to advise on regulatory matters

UK unveils £1bn sector investment push after recent setbacks

Justice Joanna Smith appointed to interim High Court role as Sir Colin Birss replaces Sir Geoffrey Vos

Oura targets Ultrahuman’s redesigned smart ring following import ban

Weil collapse leaves IP talent facing uncertain future after major expansion

Meril turns the tables on Edwards with European patent revocation

Latham lands pharma and tech expert in London

Regeneron and Amgen call a truce on two Eylea biosimilar patents

‘Doing more with less’: In-house counsel on budgets and strategy

More on this story

Editor's picks

Editor's picks

More features